As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The DERMAGLOW Division of Hetero Healthcare is dedicated to addressing a wide range of dermatological and skin health needs through a focused portfolio of therapeutic and supportive care solutions. The division aims to support healthcare professionals in managing common as well as persistent skin conditions while promoting healthier skin and improved patient well-being.
Its therapeutic portfolio focuses on areas such as acne management, fungal and bacterial skin infections, inflammatory skin conditions, pigmentation concerns, and skin repair and protection. The division also addresses supportive dermatological care through solutions that help maintain skin hydration, barrier function, and overall skin health, enabling a more comprehensive approach to dermatology.
Backed by Hetero Healthcare’s commitment to quality, innovation, accessibility, and patient-centric care, DERMAGLOW strives to provide dependable solutions across diverse dermatological needs. By combining targeted therapies with supportive skincare, the division continues to strengthen its contribution to effective skin health management and better patient care.
View by-
